Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Samsung Epis Holdings (0126Z0.KS)
Incheon, KR
Established in 2025, Samsung Epis Holdings Co., Ltd. operates as a biotechnology firm based in Incheon, South Korea. Its primary activity involves managing a varied collection of biopharmaceutical offerings.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.88% | -3.15% | -14.13% | -17.62% | -32.45% | -37.55% | +1.82% | +1.82% | +1.82% | +1.82% | +1.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
1.04B
est: 1.71T (-99.9%)
|
1.85T
1.85T – 1.85T
+8.3% YoY
|
2.11T
2.11T – 2.11T
+13.7% YoY
|
| EBITDA |
18.51M
est: 30.41B (-99.9%)
|
32.94B
32.94B – 32.94B
+8.3% YoY
|
37.45B
37.45B – 37.45B
+13.7% YoY
|
| EBIT |
-263.47M
est: -432.88B (+99.9%)
|
-468.97B
-468.97B – -468.97B
-8.3% YoY
|
-533.19B
-533.19B – -533.19B
-13.7% YoY
|
| Net Income |
353.20M
est: 384.02B (-99.9%)
|
227.86B
227.86B – 227.86B
-40.7% YoY
|
278.87B
278.87B – 278.87B
+22.4% YoY
|
| SGA |
442.75M
est: 727.44B (-99.9%)
|
788.08B
788.08B – 788.08B
+8.3% YoY
|
896.00B
896.00B – 896.00B
+13.7% YoY
|
| EPS |
14.21
est: 15,451.00 (-99.9%)
|
9,168.00
9,168.00 – 9,168.00
-40.7% YoY
|
11,220.00
11,220.00 – 11,220.00
+22.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-11 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-10 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-09 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-08 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-05 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-04 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-02 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-01 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyoung-Joon Kim | Executive Director | — | — |
| Jonjongbo Im | CEO of Samsung BioLogics Co., Ltd. | — | — |
| Kyung-Ah Kim | President, CEO & Chairman of the board | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0126Z0.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
